drugset / Trial / NCT00300404
Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
Phase 3
Completed
40 enrolled
Zentrum für Integrative Psychiatrie
Stanley Medical Research Institute · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection. As TG modulates neurotransmitter metabolism affecting serotonin and dopamine we hypothesize that this chronic persistent infection might play a role for depressive and psychotic symptomatology. Therefore, on the basis of an ex juvantibus approach, specific anti TG medication might further improve psychiatric symptomatology in affected patients. This is investigated in a double-blind, placebo-controlled, randomized treatment trial.
Timeline
- Start
- 2002-01
- Primary completion
- —
- Completion
- 2005-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pyrimethamine | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |